Martin Dietrich, MD, PhD

Martin Dietrich, MD, PhD, is a medical oncologist with The US Oncology Network Cancer Care Centers of Brevard and an assistant professor of internal medicine at the University of Central Florida College of Medicine in Orlando, Florida.

Articles by Martin Dietrich, MD, PhD

Updates in Treatment of HER2 Mutant NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 5th 2022

Dr Misako Nagasaka reviews clinical trial data presented at ESMO 2021 on therapies for NSCLC harboring HER2 exon 20 mutations.

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 2nd 2022

Dr Fernando Santini explains EGFR exon 20 insertion mutations in NSCLC and the best approaches for treating these cases.

Updates in Treatment of NSCLC with Classical EGFR Mutations

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

May 2nd 2022

A discussion on EGFR mutations in non-small cell lung cancer and the combination treatment strategies for sensitizing mutations.

Challenges Associated with Molecular Testing in NSCLC

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 19th 2022

A look at the challenges associated with different molecular testing methods and the barriers that patients with non–small cell lung cancer face in getting tested.

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 19th 2022

A panel of thought leaders describe the optimal sample to use in molecular testing in NSCLC and the appropriate time to perform testing in clinical practice.

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

ByMartin Dietrich, MD, PhD

April 12th 2022

Martin Dietrich, MD, PhD, discusses optimizing treatment options for patients with mantle cell lymphoma.

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 12th 2022

Experts in lung cancer explain their views on the critical role of liquid biopsy in molecular testing in non–small cell lung cancer.

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

ByBenjamin Levy, MD,Misako Nagasaka, MD, PhD,Timothy Craig Allen, MD, JD, FCAP,Martin Dietrich, MD, PhD,Hatim Husain, MD,Fernando C. Santini, MD

April 12th 2022

Oncologists provide insight into what actionable mutations they look for when they order molecular testing for patients with advanced non-small cell lung cancer.

Martin Dietrich, MD, PhD, of Florida Cancer Specialists

Dr. Dietrich on Future Research Directions in Lung Cancer

ByMartin Dietrich, MD, PhD

September 3rd 2021

Martin Dietrich, MD, PhD, discusses future research directions for the treatment of patients with lung cancer.

Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer

ByMartin Dietrich, MD, PhD

August 16th 2019

Martin Dietrich, MD, PhD, medical oncologist, Advent Health Cancer Institute, discusses management of diarrhea, an associated adverse event of neratinib, following data from the CONTROL trial in patients with HER2-positive breast cancer.

Martin Dietrich, MD, PhD

Articles by Martin Dietrich, MD, PhD

Updates in Treatment of HER2 Mutant NSCLC

Recent Advances in Treatment of EGFR Exon 20 Insertion Mutations in NSCLC

Updates in Treatment of NSCLC with Classical EGFR Mutations

Challenges Associated with Molecular Testing in NSCLC

Molecular Testing in NSCLC: What is the Optimal Sample and Time of Testing?

Dr. Dietrich on Optimizing Treatment Options for Patients in MCL

Liquid Biopsies in the NSCLC Molecular Testing Algorithm

Testing Approaches for Actionable Mutations in NSCLC in Clinical Practice

Dr. Dietrich on Future Research Directions in Lung Cancer

Dr. Dietrich on Optimal Adverse Event Management for Neratinib in Breast Cancer

Trending on OncLive

FDA Approves Daratumumab and Hyaluronidase Plus VRd for Newly Diagnosed Multiple Myeloma

PD-L1 Expression Is More Predictive of Response to Pembrolizumab on Metastatic Sites in High-Grade Serous Ovarian Cancer

Lurbinectedin-Based Triplet Shows Clinical Benefit in Advanced Soft Tissue Sarcoma

Ultra-Sensitive ctDNA and CSF Liquid Biopsy May Refine Monitoring and Adaptive Trial Designs in Metastatic Breast Cancer

Dr Braunstein on the FDA Approval of Subcutaneous Daratumumab With VRd For Newly Diagnosed Multiple Myeloma